Deutsche Bank AG (NYSE: DB) (FRA: DBK) initiated coverage of AtaiBeckley Inc (NASDAQ: ATAI) (FRA: B72) last week with a Buy rating and a US$12 price target. When the bank released its report, shares traded near US$3.50, which points to more than 200 per cent upside according to the financial firm’s analysts.
The team at Deutsche Bank has highlighted the company’s pipeline of new treatments for mental health conditions that resist standard medicines.
They expect these therapies to gain wider acceptance in the years ahead as regulators become more open to them.
Deutsche Bank sees AtaiBeckley as well positioned to lead in this space, with its top candidates holding potential for billions in sales if they reach the market.
AtaiBeckley’s appeal
AtaiBeckley develops investigational treatments designed to act rapidly and provide sustained effects while offering administration methods that may integrate more readily into clinical practice.
The company develops these options using specific compounds that affect brain chemistry in targeted ways. These include a nasal spray based on mebufotenin (5-MeO-DMT) for treatment-resistant depression, a thin film that dissolves in the mouth and contains standard DMT for the same condition, and a prepared form of MDMA aimed at social anxiety.
AtaiBeckley also explores non-hallucinogenic versions of related compounds for opioid use disorder and depression.
Its broad pipeline, which spans several stages of testing, sets it apart from smaller firms that depend on just one or two projects.
Read more: Psilocybin truffle maker Red Light Holland to acquire financially distressed Filament Health
Purpose of the recent merger
AtaiBeckley formed in late 2025 through the all-share merger of atai Life Sciences and Beckley Psytech.
The two organizations combined their research programs, clinical data and development teams into one stronger company that is now based in the United States.
Leaders completed the deal to speed up progress on promising treatments and move them closer to patients who need alternative options for mental health challenges.
What other analysts think
Other market observers offer generally positive but cautious views on AtaiBeckley’s future.
The broad consensus among Wall Street analysts stands at Strong Buy, with average price targets around US$13 and a range that runs from US$7 to US$25.
Separately, researchers at Simply Wall St ran cash-flow models and estimated a fair value near US$16.76 per share. They note that shares may trade well below their longer-term potential.
Positive results from recent studies on the nasal spray treatment and the company’s addition to major stock indexes have increased visibility and drawn more attention from investors.
However, observers also point out that the company still faces typical risks for a clinical-stage firm, such as the need for more funding to complete later trials. The lack of regulatory traction for clinical psychedelics in the U.S. is also of concern.
Read more: Non-profit Heroic Hearts publishes psychedelics guide for veterans
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
